Similar articles for PMID: 30072559

Year	Number of Results
2013	1
2014	3
2015	4
2016	6
2017	11
2018	49
2019	57
2020	31
2021	22
2022	18
2023	1
2024	0

1

Cancer immunotherapy with CAR-T cells - behold the future.

Graham C, Hewitson R, Pagliuca A, Benjamin R. Graham C, et al. Clin Med (Lond). 2018 Aug;18(4):324-328. doi: 10.7861/clinmedicine.18-4-324. Clin Med (Lond). 2018. PMID: 30072559 Free PMC article.

2

Cellular therapy: Immune-related complications.

Oved JH, Barrett DM, Teachey DT. Oved JH, et al. Immunol Rev. 2019 Jul;290(1):114-126. doi: 10.1111/imr.12768. Immunol Rev. 2019. PMID: 31355491 Free PMC article. Review.

3

Cytokine release syndrome: grading, modeling, and new therapy.

Liu D, Zhao J. Liu D, et al. J Hematol Oncol. 2018 Sep 24;11(1):121. doi: 10.1186/s13045-018-0653-x. J Hematol Oncol. 2018. PMID: 30249264 Free PMC article. Review.

4

Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.

Brudno JN, Kochenderfer JN. Brudno JN, et al. Blood Rev. 2019 Mar;34:45-55. doi: 10.1016/j.blre.2018.11.002. Epub 2018 Nov 14. Blood Rev. 2019. PMID: 30528964 Free PMC article. Review.

5

Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.

Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, Komanduri KV, Lin Y, Jain N, Daver N, Westin J, Gulbis AM, Loghin ME, de Groot JF, Adkins S, Davis SE, Rezvani K, Hwu P, Shpall EJ. Neelapu SS, et al. Nat Rev Clin Oncol. 2018 Jan;15(1):47-62. doi: 10.1038/nrclinonc.2017.148. Epub 2017 Sep 19. Nat Rev Clin Oncol. 2018. PMID: 28925994 Free PMC article. Review.

6

Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.

Gauthier J, Yakoub-Agha I. Gauthier J, et al. Curr Res Transl Med. 2017 Sep;65(3):93-102. doi: 10.1016/j.retram.2017.08.003. Curr Res Transl Med. 2017. PMID: 28988742 Review.

7

Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

Shum T, Kruse RL, Rooney CM. Shum T, et al. Expert Opin Biol Ther. 2018 Jun;18(6):653-664. doi: 10.1080/14712598.2018.1473368. Epub 2018 May 14. Expert Opin Biol Ther. 2018. PMID: 29727246 Free PMC article. Review.

8

Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.

Fu M, Tang L. Fu M, et al. Recent Pat Anticancer Drug Discov. 2019;14(1):60-69. doi: 10.2174/1574892814666190111120908. Recent Pat Anticancer Drug Discov. 2019. PMID: 30636615 Review.

9

Driving the CAR to the Bone Marrow Transplant Program.

Dave H, Jerkins L, Hanley PJ, Bollard CM, Jacobsohn D. Dave H, et al. Curr Hematol Malig Rep. 2019 Dec;14(6):561-569. doi: 10.1007/s11899-019-00544-6. Curr Hematol Malig Rep. 2019. PMID: 31643018 Review.

10

Managing the toxicities of CAR T-cell therapy.

Neelapu SS. Neelapu SS. Hematol Oncol. 2019 Jun;37 Suppl 1:48-52. doi: 10.1002/hon.2595. Hematol Oncol. 2019. PMID: 31187535 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

178 results

Results by year